Adi F. Gazdar

Adi F. Gazdar

Auto-generated profile, based on publicly available information

Adi F. Gazdar

UT Southwestern, Dallas, TX

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 1998 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
AGAdi F. Gazdar
Adi F. Gazdar
VKVenkatesh Kurvari
Venkatesh Kurvari
AVArvind Virmani
Arvind Virmani
LGLauren Gollahon
Lauren Gollahon
MSMasahiro Sakaguchi
Masahiro Sakaguchi
JSJerry W. Shay
Jerry W. Shay
The goal of our study was to develop a panel of tumor cell lines along with paired non‐malignant cell lines or strains collected from breast cancers, predominantly primary tumors. From a total of 189 breast tumor samples consisting of 177 primary tumors and 12 metastatic tissues, we established 21 human breast tumor cell lines that included 18 cell lines derived from primary tumors and 3 derived from metastatic lesions. Cell lines included those from patients with germline BRCA1 and FHIT gene mutations and others with possible genetic predisposition. For 19 tumor cell lines, we also established one or more corresponding non‐malignant cell strains or B lymphoblastoid (BL) lines, which included 16 BL lines and 7 breast epithelial (2) or stromal (5) cell strains. The present report describes clinical, pathological and molecular information regarding the normal and tumor tissue sources along with relevant personal information and familial medical history. Analysis of the breast tumor cell lines indicated that most of the cell lines had the following features: they were derived from large tumors with or without axillary node metastases; were aneuploid and exhibited a moderate to poorly differentiated phenotype; were estrogen receptor (ER)‐ and progesterone receptor (PR)‐negative; and overexpressed p53 and HER2/neu proteins. Of 13 patients with primary breast cancers receiving curative intent mastectomies, 7 were dead after a mean period of 10 months. Our panel of paired tumor and non‐malignant cell lines should provide important new reagents for breast cancer research. Int. J. Cancer 78:766–774, 1998.

15 October 2002 in Oncogene
Verified
Journal Article
Closed access
IWIgnacio I Wistuba
Ignacio I Wistuba
LMLi Mao
Li Mao
AGAdi F Gazdar
Adi F Gazdar

3 November 1999 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
IPIn-Won Park
In-Won Park
IWIgnacio I. Wistuba
Ignacio I. Wistuba
AMAnirban Maitra
Anirban Maitra
SMSara Milchgrub
Sara Milchgrub
AVArvind K. Virmani
Arvind K. Virmani
AGAdi F. Gazdar
Adi F. Gazdar
BACKGROUND: Several molecular changes, including loss of heterozygosity (i.e., deletion of one copy of allelic DNA sequences) and alterations in microsatellite DNA, have been detected early in the pathogenesis of lung cancer, even in histologically normal epithelium. In the bronchial epithelium of patients with lung cancer, we have determined the frequency, size, and patterns of molecularly abnormal clonal patches. METHODS: We studied formalin-fixed, paraffin-embedded samples from 16 surgically resected lung carcinomas (five squamous cell carcinomas, four small-cell carcinomas, six adenocarcinomas, and one large-cell carcinoma). From each carcinoma, we microdissected foci (each containing about 200 cells) of tumor tissue and equivalent samples of histologically normal and abnormal epithelium. Furthermore, multiple discontinuous foci of bronchial epithelium were analyzed from methanol-fixed samples from three additional patients with lung cancer (two with squamous cell carcinoma and one with adenocarcinoma). We used two-step polymerase chain reaction-based assays involving 12 microsatellite markers at seven chromosomal regions frequently deleted in lung cancer. RESULTS: Two hundred eighteen foci of nonmalignant bronchial epithelium (195 of histologically normal or slightly abnormal epithelium and 23 of dysplastic epithelium) were studied from the 19 surgically resected lobectomy specimens. Thirteen (68%) of the 19 specimens had at least one focus of bronchial epithelium with molecular changes. At least one molecular abnormality was detected in 32% of the 195 histologically normal or slightly abnormal foci and in 52% of the 23 dysplastic foci. Extrapolating from our two-dimensional analyses, we estimate that most clonal patches contain approximately 90 000 cells. Although, in a given individual, tumors appeared homogeneous with respect to molecular changes, the clonally altered patches of mildly abnormal epithelium were heterogeneous. CONCLUSIONS: Our findings indicate that multiple small clonal or subclonal patches containing molecular abnormalities are present in normal or slightly abnormal bronchial epithelium of patients with lung cancer.

5 November 1997 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
AGAdi F. Gazdar
Adi F. Gazdar
JMJohn D. Minna
John D. Minna
For the past 50 years, the winds of change have been blowing through the epidemiology and demographics of lung cancer. Worldwide changes in the incidences, sex ratios, smoking associations, and pathologic types of lung cancer have been dramatic. Such rapid, extensive, and global changes are unprecedented and have not been observed for any other major form of human cancer. In this issue of the Journal, Thun et al. ( 1 ) explore the reasons for one of these changes, the explosive rise in the relative and absolute incidences of lung adenocarcinoma in both sexes.

17 February 1999 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
AGAdi F. Gazdar
Adi F. Gazdar
JMJohn D. Minna
John D. Minna
Lung cancer is the most common cause of cancer death in the United States, and most cases follow long-term use of tobacco products ( 1 , 2 ). The first objective in lung cancer control is to prevent persons from starting to smoke and to help those who smoke to quit. Nevertheless, in the United States today, there are 48 million smokers, most of whom find it difficult to quit, with new smokers rapidly replacing the quitters ( 3 ) and smokers who die from their disease. In addition, about 40% of all new lung cancers are occurring in former smokers, who remain at high risk for developing lung cancer for many years after they stop smoking ( 4 ). Under current standard methods of diagnosis and treatment, less than 15% of patients with lung cancer will survive their disease ( 2 ). Most patients who achieve long-term survival are those with non-small-cell lung cancers (NSCLC), who have surgical resection of early stage invasive tumors without metastases (stage I) or tumors with metastases limited to the adjacent ipsilateral lymph nodes (stage II). Patients with preinvasive and microinvasive cancers that are found by cytologic examination of sputum have high survival rates (>90%) after surgical removal or localized therapy ( 2 ), but they constitute less than 1% of newly diagnosed cases ( 5 ).

1 July 2000
Verified
Journal Article
Closed access
IWI I Wistuba
I I Wistuba
JBJ Berry
J Berry
CBC Behrens
C Behrens
AMA Maitra
A Maitra
NSN Shivapurkar
N Shivapurkar
AGA F Gazdar
A F Gazdar